Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 30,887 shares, a decline of 72.6% from the May 14th total of 112,539 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 560,221 shares, the short-interest ratio is presently 0.1 days.
Oncotelic Therapeutics Price Performance
Shares of OTLC traded down $0.00 during mid-day trading on Friday, hitting $0.05. The company’s stock had a trading volume of 20,401 shares, compared to its average volume of 286,779. The firm has a 50-day moving average price of $0.04 and a 200 day moving average price of $0.06. The stock has a market capitalization of $23.29 million, a price-to-earnings ratio of 0.09 and a beta of -0.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.11 and a quick ratio of 0.11. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.11.
Oncotelic Therapeutics (OTCMKTS:OTLC – Get Free Report) last announced its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 earnings per share (EPS) for the quarter.
About Oncotelic Therapeutics
Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.
Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.
Featured Articles
- Five stocks we like better than Oncotelic Therapeutics
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
- The AI Boom Has a Hidden Winner—And It’s Not Nvidia
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
